The Leadership Team at Orano Med, comprising the President & CEO, Chief Scientific Officer, and Chief Financial Officer, is responsible for setting the strategic direction, overseeing the research and development of innovative cancer treatments, ensuring financial sustainability, and aligning administrative operations. They guide the company in advancing its targeted alpha therapy (TAT) approach to combat cancer while fostering growth and maintaining industry leadership in high-performance chelating agent technology.